# China NMPA Drug Inspection - Bozhou Haomen Traditional Chinese Medicine Pieces Co., Ltd. - Fritillaria cirrhosa

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/bozhou-haomen-traditional-chinese-medicine-pieces-co-ltd/74aa3398-3847-45fe-bee7-21bd5070c6bb/
Source feed: China

> China NMPA drug inspection for Bozhou Haomen Traditional Chinese Medicine Pieces Co., Ltd. published July 09, 2018. Drug: Fritillaria cirrhosa. The Chongqing Municipal Food and Drug Administration issued its 2018 Issue No. 3 Drug Quality Announcement on July 9, 20

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Chongqing Municipal Food and Drug Administration's Drug Quality Bulletin, Issue 3, 2018
- Company Name: Bozhou Haomen Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2018-07-09
- Drug Name: Fritillaria cirrhosa
- Inspection Finding: Non-compliant with standards regarding character/appearance and identification.
- Action Taken: Public announcement of non-compliant product
- Summary: The Chongqing Municipal Food and Drug Administration issued its 2018 Issue No. 3 Drug Quality Announcement on July 9, 2018, following comprehensive city-wide sampling inspections. This initiative aimed to strengthen drug quality oversight, regulate market order, and ensure public drug safety. The inspections revealed multiple instances of non-compliance across various traditional Chinese medicine products from several manufacturers. Key companies implicated included Anhui Fangshi Traditional Chinese Medicine Pieces Co., Ltd., Anhui Yishengtang Traditional Chinese Medicine Pieces Co., Ltd., Chengdu Jiankang Pharmaceutical Co., Ltd., Sichuan Zining Traditional Chinese Medicine Pieces Co., Ltd., and Bozhou Baishixin Traditional Chinese Medicine Pieces Co., Ltd. The primary violations involved products failing to meet quality standards stipulated in the Chinese Pharmacopoeia (2010 and 2015 Editions, Part I). Common deficiencies were identified in "Properties," "Identification" (including microscopic characteristics), "Inspection" (such as extractives), and "Content Determination" for various drugs like Cattail Pollen Charcoal, Schisandra chinensis, and Prepared Glycyrrhiza uralensis. This public announcement serves to highlight quality deficiencies, compelling manufacturers to rectify the identified issues and reinforcing the administration's dedication to upholding pharmaceutical quality standards and protecting public health.

Company: https://www.globalkeysolutions.net/companies/bozhou-haomen-traditional-chinese-medicine-pieces-co-ltd/df9113d5-2c12-4f64-ab68-0c9827cdd2b3/